Novo Nordisk A/S: Xultophy® (IDegLira) approved i
Post# of 301275
Bagsværd, Denmark, 18 September 2014 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Xultophy(®) for the treatment of type 2 diabetes mellitus in adults. The authorisation covers all 27 European Union member states. For further information Media: Mike Rulis +45 3079 3573 mike@novonordisk.com Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com Investors: Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com Jannick Lindegaard Denholt +45 3079 8519 jlis@novonordisk.com Daniel Bohsen +45 3079 6376 dabo@novonordisk.com Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com Company announcement No 58 / 2014 [HUG#1856969]
(0)
(0)